New Zealand Opens Access to Clopidogrel, Leaving Out Sanofi's Plavix
This article was originally published in PharmAsia News
TOKYO - New Zealand's Pharmaceutical Management Agency announced open access for cardiovascular drug clopidogrel, dropping patient price significantly, essentially removing Sanofi-Aventis' Plavix from the country's market
You may also be interested in...
A push in emerging markets continued in the second quarter with Big Pharma reporting flat U.S. sales and a challenging payer environment in Europe, with many reallocating resources from Europe and the U.S. to Asia and seeking partnerships in those geographies. Analysts boosted earnings per share numbers to companies that disclosed detailed emerging markets sales data, such as AstraZeneca, which started the trend in Q1, and Pfizer as the first American pharma to break out emerging market sales by product. As a recurring feature, PharmAsia News combs through quarterly earnings reports to bring together the earning season's Asia highlights.
PERTH, Australia - Mylan's Lorstat (atorvastatin) will become New Zealand's only subsidized atorvastatin generic beginning Dec. 1. In addition, the Special Authority, which requires doctors to call in to receive authority to prescribe the drug, will be removed, reducing paperwork for prescribers and widening access to the drug
PERTH, Australia - Using sole-supply providers, New Zealand generic drug prices were considerably cheaper than corresponding drugs in Australia, Britain and Canada, according to the Pharmaceutical Management Agency's annual review for 2009